|
AU2012254946A1
|
|
CPCR agonists
|
|
GB201208318D0
|
|
Novel compounds
|
|
GB201207804D0
|
|
Novel compositions
|
|
GB201207359D0
|
|
Compounds for the treatment of metabolic disorders
|
|
GB201207363D0
|
|
Compounds for the treatment of metabolic disorders
|
|
GB201201744D0
|
|
GPR119 agonists useful in the treatment of type II diabetes
|
|
GB201201720D0
|
|
Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
|
|
GB201121193D0
|
|
Compounds useful as GPR119 agonists
|
|
WO2012066077A1
|
|
1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
|
|
GB201114389D0
|
|
Novel compounds
|
|
HK1151757A1
|
|
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
|
GB201108810D0
|
|
Novel compositions
|
|
TW201209054A
|
|
Novel compounds
|
|
GB201106154D0
|
|
Compounds for the treatment of metabolic disorders
|
|
GB201106142D0
|
|
Compounds for the treatment of metabolic disorders
|
|
GB201104965D0
|
|
Gpr119 agonists for use in the treatment or prevention of dyslipidaemia in humans
|
|
GB201103283D0
|
|
Heterocyclic GPCR agonists
|
|
GB201100230D0
|
|
GPR119 agonists for use in the treatment or prevention of overweight and obesity or for procuring weight-loss in humans
|
|
GB201020909D0
|
|
Novel compounds
|
|
GB201019547D0
|
|
Novel compounds
|
